Facebook
X
LinkedIn
Forward
Navigating the Latest in Pulmonary Arterial Hypertension: Implementing Guidelines Amidst a Changing Treatment Landscape
Pulmonary arterial hypertension (PAH) is a rare, progressive form of pulmonary hypertension characterized by elevated pulmonary arterial pressure and vascular remodeling, which can lead to right-sided heart failure and death if untreated. Despite its rarity, the prevalence of PAH is increasing, with significant knowledge gaps among clinicians regarding risk assessment, treatment goals, and advancements in therapies. The 2022 ESC/ERS guidelines introduced updates to the definition, screening, and treatment of PAH, reflecting the rapid evolution of therapeutic options.
This webinar will discuss how managing PAH remains complex and emphasize the need for clinicians to adopt goal-directed therapy and optimize treatment strategies to improve patient outcomes.
Target Audience
The educational design of this activity addresses the needs of U.S. based cardiologists, pulmonologists, rheumatologists, primary care physicians and advanced practice providers involved in managing patients with PAH.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients with PAH based on symptoms, risk factors, and screening strategies outlined in evidence-based guidelines
- Explain the latest PAH guidelines and the importance of risk assessment and treatment goals.
- Define the mechanisms of action, efficacy, and safety of current, recently FDA approved and emerging therapeutic options for PAH
- Review individualized treatment regimens based on the multidisciplinary approach to care for PAH that considers treatment goals, long-term assessment, and comorbidities in order to improve patient outcomes
Additional Information
| Attachment | Size |
|---|---|
 Downloadable Slides | 3.3 MB |
| PAH Peer-peer Clinical Toolkit 2025 | 3.31 MB |
Vallerie V. Mclaughlin, MD, FACC, FAHA
Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Richard N. Channick, MD
Saul Brandman Endowed Chair in Pulmonary Arterial Hypertension
Co-Director, Pulmonary Vascular Disease Program
Director, Acute and Chronic Thromboembolic Disease Program
Director, Advanced Pulmonary Vascular Disease Fellowship
Professor of Medicine
Pulmonary and Critical Care Division
David Geffen School of Medicine at UCLA
Los Angeles, CA
ESTIMATED TIME TO COMPLETE ACTIVITY
1.25 hours
EDUCATIONAL GRANT SUPPORT
Supported by an independent medical educational grant from Merck Sharp & Dohme LLC.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Cardiometabolic Health Congress (CMHC). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
Partners designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
Partners designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - ACPE UAN is JA4008073-9999-25-418-H01-P Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from December 22, 2025, through December 22, 2026.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For additional information about the accreditation of this activity, please visit https://partnersed.com
DISCLOSURES
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. McLaughlin, faculty for this educational activity, discloses the following:
- Grant support: PI- Gossamer-Bio, Keros Liquidia, Sub-I Janssen, Merck/Aceleron
- Scientific Consulting: AllRock, CVS/Caremark, L.L.C., Corvista, Gossamer Bio, Janssen, Inhibikase, Keros, Liquidia, Merck, Morphic, Novartis, Regeneron, Respira, Roivant, United Therapeutics
Dr. Channick, faculty for this educational activity, discloses the following:
- Speaker: Merck, Johnson and Johnson
- Advisor: Merck, Johnson and Johnson, Liquidia
- Consultant: Gossamer
- Researcher: Pulmovant
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.